Patents by Inventor Ralph Weissleder

Ralph Weissleder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240115514
    Abstract: Disclosed herein are nanoparticles that include one or more cyclodextrin moieties crosslinked by a linker. The cyclodextrin moieties can complex therapeutic (e.g., anticancer) agents, and can be used to treat diseases such as cancer.
    Type: Application
    Filed: June 28, 2023
    Publication date: April 11, 2024
    Inventors: Christopher Rodell, Ralph Weissleder
  • Publication number: 20240058455
    Abstract: The present disclosure provides bioorthogonal linkers and reagents, including trans-cyclooctene (“TCO”)- and tetrazine (“Tz”)-containing compounds. In a general aspect, the present disclosure provides reagents, conjugates, and bioactive molecules containing a trans-cyclooctene (“TCO”) fragment. Examples of TCO fragments include: Formulae (I) and (II).
    Type: Application
    Filed: October 4, 2021
    Publication date: February 22, 2024
    Inventors: Jonathan Carlson, Hannes Mikula, Ralph Weissleder
  • Patent number: 11850216
    Abstract: The present invention, in some aspects, provides methods, reagents, compositions, and kits for the radiolabeling of proteins, for example, of proteins useful for positron emission tomography (PET) or single-photon emission computed tomography (SPECT) (e.g., for diagnostic and therapeutic applications), using sortase-mediated transpeptidation reactions. Some aspects of this invention provide methods for the conjugation of an agent, for example, a radioactive agent or molecule to diagnostic or therapeutic peptides or proteins. Compositions comprising sortagged, radiolabeled proteins as well as reagents for generating radiolabeled proteins are also provided. Kits comprising reagents useful for the generation of radiolabeled proteins are provided, as are precursor proteins that comprise a sortase recognition motif.
    Type: Grant
    Filed: January 8, 2020
    Date of Patent: December 26, 2023
    Assignees: Whitehead Institute for Biomedical Research, The General Hospital Corporation
    Inventors: Mohammad Rashidian, Hidde L. Ploegh, Ralph Weissleder, Edmund J. Keliher
  • Publication number: 20230266348
    Abstract: Aspects of the present disclosure provide devices and methods for rapid, quantitative, on-site detection of controlled substances. Devices include a sample processing module and a sensor cartridge, and optionally a detection cradle.
    Type: Application
    Filed: July 26, 2021
    Publication date: August 24, 2023
    Inventors: Hakho Lee, Ralph Weissleder, Hojeong Yu, Jinwoo Cheon
  • Publication number: 20230160809
    Abstract: Systems, methods, and device can be used to detect target extracellular vesicles (“EVs”). One example of a method includes obtaining a nano-plasmonic array including nanostructures configured to amplify one or more specific wavelengths of electromagnetic radiation, flowing a liquid sample over the nano-plasmonic array, optionally labeling target EVs captured on the nano-plasmonic array with one or more reporter groups, projecting electromagnetic radiation onto the labeled target EVs captured on the nano-plasmonic array, and capturing an image of the target EVs by receiving electromagnetic radiation emitted, scattered, or reflected by the EVs or by reporter groups on the labeled target EVs.
    Type: Application
    Filed: April 14, 2021
    Publication date: May 25, 2023
    Inventors: Hyungsoon Im, Ralph Weissleder
  • Publication number: 20230123746
    Abstract: Systems, methods, and devices are described herein for detecting and/or monitoring target extracellular vesicles (“EVs”), e.g., to detect and/or monitor cancer treatment, such as breast cancer, in a subject. The methods can include obtaining a nano-plasmonic array including nanostructures configured to amplify one or more specific wavelengths of electromagnetic radiation, flowing a liquid sample over the nano-plasmonic array, optionally labeling target EVs captured on the nano-plasmonic array with one or more reporter groups, projecting electromagnetic radiation onto the labeled target EVs captured on the nano-plasmonic array, and capturing an image of the target EVs by receiving electromagnetic radiation emitted, scattered, or reflected by the labeled target EVs or by reporter groups on the labeled target EVs.
    Type: Application
    Filed: October 14, 2022
    Publication date: April 20, 2023
    Inventors: Hyungsoon Im, Ralph Weissleder
  • Publication number: 20230098031
    Abstract: The present application provides a compound of Formula (A), or a pharmaceutically acceptable salt thereof, wherein R1, L1, n, L2, m, L3, p, Y2, and Y3 are as described herein. Methods of using the compound of Formula (A) to prepare an antibody conjugate, and methods of using these conjugates for cellular imaging are also described.
    Type: Application
    Filed: December 10, 2020
    Publication date: March 30, 2023
    Inventors: Ralph Weissleder, Jonathan C.T. Carlson, Jina Ko
  • Publication number: 20230070693
    Abstract: The present disclosure provides, in some embodiments, devices, methods, and kits for purifying extracellular vesicles (EVs) using size exclusion chromatography in tandem with cation exchange chromatography, which can be referred to as dual-mode chromatography (DMC).
    Type: Application
    Filed: February 16, 2021
    Publication date: March 9, 2023
    Inventors: Hakho Lee, Ralph Weissleder, Jan Van Deun
  • Patent number: 11525778
    Abstract: The disclosure features systems and methods for measuring and diagnosing target constituents bound to labeling particles in a sample. The systems include a radiation source, a sample holder, a detector configured to obtain one or more diffraction patterns of the sample each including information corresponding to optical properties of sample constituents, and an electronic processor configured to, for each of the one or more diffraction patterns: (a) analyze the diffraction pattern to obtain amplitude information and phase information corresponding to the sample constituents; (b) identify one or more particle-bound target sample constituents based on at least one of the amplitude information and the phase information; and (c) determine an amount of at least one of the particle-bound target sample constituents in the sample based on at least one of the amplitude information and the phase information.
    Type: Grant
    Filed: July 27, 2020
    Date of Patent: December 13, 2022
    Assignee: The General Hospital Corporation
    Inventors: Ralph Weissleder, Hakho Lee, Hyungsoon Im, Cesar Castro
  • Publication number: 20220325271
    Abstract: Described herein are methods, uses, and kits for droplet-based single cell sequencing of nucleic acids from extracellular vesicles. Specifically, the disclosure provides methods of analyzing protein compositions from individual extracellular vesicles (EVs) from biological samples including pluralities of EVs, the methods comprising labeling the EVs with antibody-DNA conjugates; encapsulating the labeled EVs, barcoded beads, and an extension reagent mix into droplets; within one or more of the droplets, hybridizing the antibody-DNA conjugates with a hybridization region in the barcoded beads; generating RNA from the DNA; synthesizing cDNA from the RNA; amplifying and sequencing the cDNA from one or more individual EVs from the biological sample; and analyzing the sequence of the cDNA from individual EVs to define their protein composition.
    Type: Application
    Filed: September 28, 2020
    Publication date: October 13, 2022
    Inventors: Jina Ko, Ralph Weissleder, Yongcheng Wang, David A. Weitz
  • Publication number: 20220062428
    Abstract: The present application provides a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein L1, L2, L3, n, m, p, X, T, TR, and D are as described herein. Methods of using of these compounds to treat diseases advantageously treatable by drug D are also described.
    Type: Application
    Filed: December 12, 2019
    Publication date: March 3, 2022
    Inventors: Miles A. Miller, Ralph Weissleder, Hannes Mikula
  • Patent number: 11208390
    Abstract: The present application relates to functionalized 1,2,4,5-tetrazine compounds. The compounds are useful in compositions and methods using bioorthogonal inverse electron demand Diels-Alder cycloaddition reactions for the rapid and specific covalent delivery of a “payload” to a ligand bound to a biological target.
    Type: Grant
    Filed: March 2, 2020
    Date of Patent: December 28, 2021
    Assignee: The General Hospital Corporation
    Inventors: Scott A. Hilderbrand, Neal K. Devaraj, Ralph Weissleder, Mark R. Karver
  • Publication number: 20210355221
    Abstract: Methods of treating a subject (e.g., a mammalian, preferably human, subject) with cancer, e.g., with melanoma, comprising administering a combination of an inhibitor of the non-canonical NFkB pathway and a checkpoint inhibitor.
    Type: Application
    Filed: October 18, 2019
    Publication date: November 18, 2021
    Inventors: Mikael J. Pittet, Ralph Weissleder, Christopher Garris, Sean Arlauckas
  • Patent number: 11125745
    Abstract: Target analyte detection devices include a housing having a potentiostat and a microcontroller coupled to the potentiostat. The device also includes a substrate having a plurality of electrodes on a first surface of the substrate. A first set of electrodes of the plurality of electrodes defines a first sample detection region. The substrate is removably attachable to the housing such that the first set of electrodes is coupled to the potentiostat upon attaching the substrate to the housing. The device also includes a magnet assembly couplable to a second surface of the substrate. The magnet assembly includes a magnet positioned in the magnet assembly such that a magnetic field from the magnet extends through the substrate and the first set of electrodes into an area above the first sample detection region upon coupling the magnet assembly to the substrate.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: September 21, 2021
    Assignees: The General Hospital Corporation, The Brigham and Women's Hospital, Inc.
    Inventors: Hakho Lee, Ralph Weissleder, Sangmoo Jeong, Jongmin Park, Cesar Castro, Hsing-Ying Lin, Jamil Azzi
  • Publication number: 20210080390
    Abstract: The disclosure features systems and methods for measuring and diagnosing target constituents bound to labeling particles in a sample. The systems include a radiation source, a sample holder, a detector configured to obtain one or more diffraction patterns of the sample each including information corresponding to optical properties of sample constituents, and an electronic processor configured to, for each of the one or more diffraction patterns: (a) analyze the diffraction pattern to obtain amplitude information and phase information corresponding to the sample constituents; (b) identify one or more particle-bound target sample constituents based on at least one of the amplitude information and the phase information; and (c) determine an amount of at least one of the particle-bound target sample constituents in the sample based on at least one of the amplitude information and the phase information.
    Type: Application
    Filed: July 27, 2020
    Publication date: March 18, 2021
    Inventors: Ralph Weissleder, Hakho Lee, Hyungsoon Im, Cesar Castro
  • Publication number: 20210038748
    Abstract: This document relates to compounds useful for targeting PARP1. Also provided herein are methods for using such compounds to detect and image cancer cells.
    Type: Application
    Filed: May 14, 2020
    Publication date: February 11, 2021
    Inventors: Thomas Reiner, Edmund J. Keliher, Ralph Weissleder
  • Publication number: 20200408687
    Abstract: In an exemplary method, a sample is provided. The sample contains a polymerase molecule, a receptor molecule containing a fluorophore, and a detector molecule. The detector molecule is configured to, in the presence of a target nucleic acid, inhibit the polymerase molecule from cleaving the fluorophore. A level of fluorescence anisotropy from the sample is detected to determine the absence or presence of the target nucleic acid in the sample.
    Type: Application
    Filed: March 27, 2017
    Publication date: December 31, 2020
    Inventors: Ralph Weissleder, Hakho Lee, Kisoo Park, Chen-han Huang
  • Publication number: 20200384137
    Abstract: The present invention, in some aspects, provides methods, reagents, compositions, and kits for the radiolabeling of proteins, for example, of proteins useful for positron emission tomography (PET) or single-photon emission computed tomography (SPECT) (e.g., for diagnostic and therapeutic applications), using sortase-mediated transpeptidation reactions. Some aspects of this invention provide methods for the conjugation of an agent, for example, a radioactive agent or molecule to diagnostic or therapeutic peptides or proteins. Compositions comprising sortagged, radiolabeled proteins as well as reagents for generating radiolabeled proteins are also provided. Kits comprising reagents useful for the generation of radiolabeled proteins are provided, as are precursor proteins that comprise a sortase recognition motif.
    Type: Application
    Filed: January 8, 2020
    Publication date: December 10, 2020
    Applicants: Whitehead Institute for Biomedical Research, The General Hospital Corporation
    Inventors: Mohammad Rashidian, Hidde L. Ploegh, Ralph Weissleder, Edmund J. Keliher
  • Publication number: 20200338011
    Abstract: Disclosed herein are nanoparticles that include one or more cyclodextrin moieties crosslinked by a linker. The cyclodextrin moieties can complex therapeutic (e.g., anticancer) agents, and can be used to treat diseases such as cancer.
    Type: Application
    Filed: October 19, 2018
    Publication date: October 29, 2020
    Inventors: Christopher Rodell, Ralph Weissleder
  • Publication number: 20200289667
    Abstract: Compositions comprising a macrophage-targeted carrier and one or more therapeutic agents that modulate cardiac conductance, and methods of using the same for treating subjects with cardiac rhythm disorders, e.g., bradycardia or tachycardia.
    Type: Application
    Filed: June 1, 2020
    Publication date: September 17, 2020
    Inventors: Maarten Hulsmans, Matthias Nahrendorf, Ralph Weissleder